Written by Amanda Collins,
For most of modern medical history, treatment has been built around the average patient. Clinical trials enroll a defined population, researchers measure how that population responds to a drug or intervention, and the results become the basis for guidelines that are then applied broadly. This approach has produced enormous public health gains, but it has an inherent limitation: no single patient is actually “average.” As healthcare professionals increasingly recognize, the gap between population-level evidence and individual patient response is where a great deal of ineffective, and sometimes harmful, care originates. Personalized, or precision, medicine is the growing effort to close that gap.
The Problem with Standardized Treatment
Clinical guidelines are, by design, statistical summaries. A dosing recommendation or first-line therapy is typically the option that performed best on average across a trial population. But “best on average” can obscure enormous variation underneath. A medication that produces strong benefit in the majority of trial participants may be ineffective, or even harmful, in a meaningful minority. Genetics, metabolism, body composition, comorbid conditions, and lifestyle factors all influence how an individual actually responds to a given intervention, yet standardized protocols often cannot account for all of these variables at the point of care.
Guidelines still serve an essential purpose: they give clinicians a defensible, evidence-based starting point, and quality-of-care frameworks like those taught in health care quality management certification programs exist precisely to help systems balance consistency with outcomes. But a starting point is not a finish line, and treating it as one is where standardization tends to fail patients.
This is part of why interest in individualized health optimization has grown well beyond the prescription pad. Patients are increasingly proactive about supporting their own physiology based on their personal biomarkers and goals, whether that means requesting more detailed lab panels or exploring targeted nutritional support such as premium NMN supplements, which some patients pursue as part of a broader, individualized approach to cellular energy metabolism and healthy aging. The larger point clinicians should take from this trend is not about any one product category. It’s that patients themselves are already thinking about their care in more personalized terms than the standard treatment model typically offers.
The consequences of ignoring this variability are not trivial. In the case of pharmaceuticals, adverse drug reactions are estimated to be the fourth leading cause of death in the United States, contributing to roughly 128,000 deaths and $136 billion in costs annually, a burden larger than the total cost of cardiovascular or diabetes care.
A meaningful share of that burden traces back to treatment decisions made for the “average” patient rather than the one actually sitting in the exam room.
Why People Respond Differently
The biological basis for variable treatment response is well established. Pharmacogenomics, the study of how genetic variation affects drug metabolism, has shown that genetic factors alone can account for anywhere from 20% to 95% of the variability seen in drug response, depending on the medication and condition involved.
Variants in genes encoding cytochrome P450 enzymes, for example, determine whether a patient metabolizes a given drug quickly, slowly, or not at all, directly affecting both efficacy and the risk of toxicity.
Genetics is only one piece of the puzzle. Body composition and age change how drugs distribute and clear from the body. Pre-existing conditions can alter organ function in ways that affect dosing safety margins. And a newer area of research, sometimes called pharmacomicrobiomics, has demonstrated that differences in gut microbiome composition can meaningfully influence drug absorption and metabolism, adding yet another layer of individual variability that standard protocols rarely capture.
Taken together, these factors explain why two patients with the same diagnosis, given the same medication at the same dose, can have entirely different outcomes.
Where This Shows Up in Practice
These effects are not theoretical: they show up across common areas of clinical care:
Antidepressant prescribing is a frequently cited example of trial-and-error medicine. In the landmark STAR*D trial, only about a third of patients achieved remission on their first antidepressant, with response rates dropping further at each subsequent treatment step.
Much of this variability is now understood to relate to genetic differences in how patients metabolize SSRIs and other psychiatric medications, which is why pharmacogenomic testing prior to prescribing is gaining traction in psychiatric practice.
Statin response varies considerably as well. Some patients achieve significant LDL reduction on a standard dose, while others see minimal benefit or experience side effects such as myopathy, often tied to genetic differences in drug transport and metabolism.
Cancer treatment has arguably moved furthest toward personalization. Tumor genomic profiling now routinely informs chemotherapy selection, allowing oncologists to match specific targeted therapies to the molecular characteristics of a patient’s tumor rather than relying solely on cancer type and stage. A related example is clopidogrel therapy in cardiovascular medicine, where genetic variation in the CYP2C19 gene means up to 30% of patients treated for acute coronary syndrome show a poor response to the standard regimen, with heritability accounting for the majority of that variability.<sup>6</sup>
Diabetes management protocols illustrate a different kind of mismatch, not pharmacogenomic, but behavioral. Standardized dietary and medication regimens frequently fail to account for a patient’s work schedule, food access, cultural food practices, or comorbid conditions, all of which affect whether a plan is actually sustainable.
What Personalized Care Looks Like Instead
Precision medicine does not mean discarding evidence-based guidelines; it means using them as a starting point rather than a final answer, then adjusting based on the individual in front of the clinician. In practice, this looks like several concrete shifts in care delivery:
- Genetic testing before prescribing, particularly for drug classes with well-documented pharmacogenomic variability, such as certain antidepressants, antiplatelet agents, and chemotherapy drugs.
- Biomarker-driven treatment planning, using more thorough bloodwork and diagnostic panels to guide decisions rather than defaulting to standard dosing based on age and weight alone.
- Lifestyle-integrated care plans that account for a patient’s actual daily routine, occupation, and support system, rather than assuming a uniform capacity to follow a rigid protocol.
- Clinician-led assessment over protocol-driven defaults, restoring the physician’s judgment as the final filter through which population-level guidelines are applied to a specific patient. This is also where case management plays an underappreciated role: professionals trained through programs like AIHCP’s case management certification are often the ones coordinating across specialists, translating biomarker-driven plans into something a patient can actually follow day to day.
This shift is also visible in the growth of specialized, condition-focused clinics that build their entire care model around individualized assessment rather than generic primary care visits. Men’s health has become a particularly active area for this kind of specialization, with dedicated practices offering in-depth hormone panels, metabolic testing, and tailored treatment plans that a standard 15-minute appointment often cannot accommodate. A patient in the Midwest, for instance, might seek out a men’s health clinic in St. Louis specifically because it offers more comprehensive, individualized diagnostic workups for concerns like low testosterone, fatigue, or metabolic changes than a general practice visit typically allows. This trend reflects a broader consumer expectation: patients want their care to be built around their specific physiology, not a generic template.
The Role of Technology
Much of what makes personalized care more feasible today than it was a decade ago comes down to technology. Direct-to-consumer and clinician-ordered genetic testing has become dramatically more affordable, making pharmacogenomic screening realistic for routine use rather than a specialty-only tool. Telehealth platforms have expanded access to specialists who can interpret complex biomarker data, particularly for patients outside major metropolitan areas. Wearable devices and continuous monitoring tools now generate real-time physiological data (glucose trends, heart rate variability, sleep architecture) that can inform treatment adjustments far more responsively than periodic office visits alone.
Electronic health records with integrated clinical decision support are also beginning to flag gene-drug interactions automatically, reducing the burden on clinicians to remember every relevant pharmacogenomic interaction. Collectively, these tools are lowering the cost and complexity of individualized assessment, moving precision medicine from a resource reserved for academic medical centers toward something achievable in routine practice.
Takeaway
Personalized medicine is not about adding complexity for its own sake, nor is it a rejection of the clinical trial evidence that underlies modern medical guidelines. It is about recognizing that guidelines describe an average patient who does not exist in any single exam room. The genetic makeup, metabolism, lifestyle, and health history of the actual person receiving care all shape how that care should be delivered. As genetic testing, biomarker panels, and digital health tools become more accessible, healthcare professionals have a growing set of tools to close the gap between population averages and individual outcomes, and an increasing responsibility to use them. The National Institutes of Health has framed this shift plainly: medicine has long relied on an expected “average” response, and precision medicine exists to correct for the patients that approach leaves behind. For healthcare professionals looking to build these principles into their own practice, resources like AIHCP’s continuing education and certification programs offer a practical next step toward more individualized, patient-centered care.
References
- Medical Laboratory Observer. (n.d.). The role of pharmacogenomics in precision medicine.
- PMC. (2024). The role of pharmacogenomics studies for precision medicine among Ethiopian patients and their clinical implications: A scoping review.
- IntechOpen. (2023). Pharmacogenomics – A prospective journey towards precision medicine.
- PMC. (2023). Drug-microbiota interactions: An emerging priority for precision medicine.
- Psychiatric Times / Carlat Publishing. (2024–2026). STAR*D reanalysis and antidepressant remission rate coverage.
- PMC. (2018). Pharmacogenomic impact of CYP2C19 variation on clopidogrel therapy in precision cardiovascular medicine.
About the Author
Amanda Collins is a healthcare writer and patient advocacy specialist with over a decade of experience covering clinical practice, care coordination, and health system design. Her work focuses on translating complex health policy and research into rigorous, evidence-informed content for clinical professionals. Amanda has contributed to a range of professional health publications and holds a particular interest in neurodevelopmental intervention, chronic disease management, and the structural determinants of healthcare quality.
Please also review AIHCP’s Managed Health Care Certification program and CE courses see if it meets your academic and professional goals. These programs are online and independent study and open to qualified professionals seeking a four year certification